Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Abstract

Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care. (Funded by Boehringer Ingelheim and Eli Lilly; EMPA-REG OUTCOME ClinicalTrials.gov number, NCT01131676.).

Keywords

Affiliated Institutions

• University of Würzburg DE
• Boehringer Ingelheim (Germany) DE
• University of Toronto CA
• George Washington University US
• Boehringer Ingelheim (Taiwan) TW
• Boehringer Ingelheim (United States) US
• Lunenfeld-Tanenbaum Research Institute CA
• Yale University US
• Boehringer Ingelheim (Norway)

Related Publications